Category

Research Review
Highlights include: Daratumumab + standard care in newly diagnosed MM OS with daratumumab + bortezomib/melphalan/prednisone in newly diagnosed MM Frontline treatment of elderly non transplant-eligible MM patients using cyclophosphamide, bortezomib, dexamethasone Download here: Multiple Myeloma Research Review Issue 33
Continue Reading
Highlights include: • Once-weekly vs twice weekly carfilzomib for newly diagnosed MM • Negative trials for pembrolizumab in treatment naive and relapsed/refractory MM • Daratumumab plus dexamethasone in triple refractory MM Download here: Multiple Myeloma Research Review Issue 32
Continue Reading
The impact of age, ethnicity and socio-economic deprivation in the era of novel anti-myeloma agents is unclear. Using linked national data from New Zealand, we evaluated the incidence, prevalence and overall survival (OS) of individuals who were diagnosed with myeloma between 2004 and 2016. The crude incidence rate increased from 5.42 to 8.47/100 000 and...
Continue Reading
Highlights include: • Increased novel agent access in NZ improved MM survival • Pomalidomide-based regimens for relapsed/refractory MM • Daratumumab, lenalidomide + dexamethasone for untreated myeloma Download here: Multiple Myeloma Research Review Issue 31
Continue Reading
Highlights include: • Anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. • MGUS risk in relatives of patients with multiple myeloma. • Costs of peripheral neuropathy in patients treated for multiple myeloma. Download here: Multiple Myeloma Research Review Issue 30
Continue Reading
This guide is written for people who have been diagnosed with myeloma. It will also be helpful for their families, friends and health professionals. It provides information about how to live well with myeloma by explaining how to cope with the physical symptoms and side effects and practical implications of living with the disease. Being...
Continue Reading
Highlights include: Real-life safety and efficacy of autologous SCT in elderly MM Lenalidomide maintenance vs. observation for newly diagnosed MM Subclonal TP53 copy number is associated with MM prognosis Download here – Multiple Myeloma Research Review Issue 29
Continue Reading
Research Review Multiple Myeloma Summit Highlights include:  High risk MM outcomes 5-year results for CyBorD MRD for guiding myeloma treatment Burden of MM in NZ Download here
Continue Reading
Issue 28 of Multiple Myeloma Research Review. Highlights include:  Elotuzumab monotherapy for smouldering MM Thereapetuc vulnerability of MM to Pri-17-92 inhibition Identification of novel mutational drivers reveals oncogene dependencies in MM Patient reported health-related Q0L from TOURMALINE-MM1 Download here
Continue Reading
Issue 27 of Multiple Myeloma Research Review Highlights include:  Low dose lenalidomide + dexamethasone in newly diagnosed POEMS syndrome. Loss of heterozygosity indicates homologous repair deficiency in MM. Treatment intensification with SCT + lenalidomide in new MM in CR. Download here
Continue Reading
1 2

Floor 7, 90 The Terrace
Wellington Central
New Zealand